Kevin Friedman

Kevin Friedman is the current Chief Scientific Officer & President at Kelonia Therapeutics. Kevin has also previously held positions at bluebird bio, Georgia Health Sciences Health System, and the National Cancer Institute.

Friedman graduated with a degree in biology from the University of Oregon in 2004. Kevin then went on to complete their doctoral training at the National Cancer Institute, where they focused on cancer research. In 2009, they joined Stealth NewCo as a Graduate Research Assistant.

In 2012, Friedman left the National Cancer Institute to take a position as Cancer Center Faculty at Georgia Health Sciences Health System. Kevin then moved to bluebird bio in 2013, where they worked their way up from Scientist to Senior Director. Kevin held this position until July 2019, when they assumed their current role at Kelonia Therapeutics.

Maggie Lau - Associate Scientist II, Ryan Lynch - VP, Finance, and Howie Latimer - Principal Associate Scientist report to Kevin Friedman.